$50 Million

miRagen Therapeutics Inc

At-the-market Offering

Miragen Therapeutics Inc is a US-based clinical-stage biopharmaceutical company discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapeutics. The company's main product candidates, MRG-106, MRG-201, MRG-107, and MRG-110. MRG-106 and MRG-201 are currently in Phase 1 clinical trials. The company mainly focuses on developing such therapeutics which will target blood cancers, pathological fibrosis, and revascularization.